Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

AbbVie’s Rinvoq approved by MHRA for Crohn’s disease

Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms

A bundle of nerves

Medical experts have determined that we need to screen everyone for anxiety − and I mean everyone

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

- PMLiVE

Kite and Arcellx close multiple myeloma collaboration agreement

This haematological malignancy is the third most common  in Europe and the US and is incurable for most patients

- PMLiVE

Patient Recruitment: Think Global, Act Local

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust...

- PMLiVE

The challenges of identifying rare diseases

With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

- PMLiVE

Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis

Spesolimab prevented flares in adolescents and adult GPP patients for up to 48 weeks

- PMLiVE

Microfoundations matter

If you want to change in 2023, sweat the small stuff

- PMLiVE

5 ways we’re enhancing our services to support our clients in 2023

Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

Avalere Health

- PMLiVE

Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children

If approved, the medicine would be the first and only targeted option in the EU for this age group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links